Overview: Serum Viscosity TestIntroduction: The Serum Viscosity Test measures serum viscosity to diagnose hyperviscosity syndrome, causing headaches. Following 2023 ASH guidelines, it uses biochemical methods for high specificity, supporting general screening. This test is critical for guiding diagnosis, treatment planning, and improving outcomes in biochemistry for patients with suspected hyperviscosity syndrome.
Other Names: Serum Viscosity Assay, Blood Viscosity Test.
FDA Status: Laboratory-developed test (LDT), meeting biochemistry standards for diagnostic accuracy.
Historical Milestone: Serum viscosity testing began in the 1960s with hematological research. Biochemical methods improved in the 2000s, enhancing diagnostic precision.
Purpose: Measures serum viscosity to diagnose hyperviscosity syndrome, guides treatment, and evaluates patients with headaches.
Test Parameters: 1. Serum Viscosity
Pretest Condition: No fasting required. Collect serum. Report history of headaches or hematological symptoms.
Specimen: Serum (SST, 2-5 mL). Transport in a biohazard container.
Sample Stability at Room Temperature: 8 hours
Sample Stability at Refrigeration: 7 days
Sample Stability at Frozen: 6 months
Medical History: Document headaches, visual changes, or history of hyperviscosity syndrome. Include current medications, especially for multiple myeloma.
Consent: Written consent required, detailing the tests purpose, hyperviscosity syndrome implications, and risks of sample collection.
Procedural Considerations: Uses viscometry to measure serum viscosity. Results are available in 1-2 days, supporting clinical decisions. Performed in laboratories, often for hyperviscosity diagnosis.
Factors Affecting Result Accuracy: Sample hemolysis or improper storage can affect results. High protein levels may increase viscosity.
Clinical Significance: Elevated viscosity confirms hyperviscosity syndrome, guiding plasmapheresis or chemotherapy. Normal levels may require protein electrophoresis.
Specialist Consultation: Consult a hematologist for result interpretation and treatment planning.
Additional Supporting Tests: Protein electrophoresis, immunoglobulin levels, or bone marrow biopsy to confirm hyperviscosity syndrome diagnosis.
Test Limitations: Non-specific for underlying cause; clinical correlation is needed. Sample quality affects sensitivity.
References: ASH Hematology Guidelines, 2023; Blood, Rajkumar SV, 2022.
